Class: Antiretroviral Agent, Protease Inhibitor
Dosage Forms. Capsule: 100 mg, 150 mg, 200 mg, 300 mg
Common FDA Label Indication, Dosing, and Titration.
1. Treatment of HIV-1 infections in combination with at least two other antiretroviral agents: Adults and Children ≥13 y and ≥39 kg, 300-400 mg po daily; Children <13 y, weight based and used in combination with ritonavir
Off-Label Uses. None
MOA. Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.
Drug Characteristics: Atazanavir
Medication Safety Issues: Atazanavir
Drug Interactions: Atazanavir
Adverse Reactions: Atazanavir
Efficacy Monitoring Parameters. HIV viral load, CD4 count, drug levels with some concomitant medication.
Toxicity Monitoring Parameters. Liver function tests, bilirubin, ECG monitoring in patients with prolonged PR interval or with concurrent AV nodal blocking drugs, CBCs, lipid panel.
Key Patient Counseling Points. Multiple, potentially serious drug interactions; do not take new medications without consulting healthcare provider. Take with food. Do not open, chew, or crush capsule. Does not prevent transmission of HIV; practice safe sex.
Clinical Pearls. Not recommended for children less than 6 y of age. Atazanavir dose varies with concurrent medications, pregnancy, and prior HIV therapy.